Get the SPI Wire

REVIVA PHARMACEUTICALS HOLDINGS, INC.

OTCQB:RVPH
Annual Meeting

of Shareholders

MEETING DATE

12/18/2026
DEF 14A FILED
11/09/2026
PUBLISHED
11/09/2026 9:15 pm
TIME TO PUBLISH
11/11/2026
METHODOLOGY
approve
EXCHANGE OTCQB:RVPH· CUSIP 76152G209 · CLASS common stock · CIK 0001742927

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
0
AGAINST
0
WITHHOLD
5
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To elect five director nominees to serve as directors until the next annual meeting of stockholders
board
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing discloses five director nominees are standing for election.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To ratify the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026
auditor
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states there were no disagreements or reportable events with Moss Adams through June 3, 2025.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve, on an advisory basis, the executive compensation of the Company’s named executive officers as described in the proxy statement
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing describes the named executive officer compensation in this proxy statement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027, subject to the Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the purpose is to seek an uplisting and meet initial listing minimum bid requirements.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if the number of shares of common stock present or represented by proxy at the Annual Meeting and voting “FOR” any of the foregoing proposals presented are insufficient to approve any of said proposals
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states adjournment may be used to solicit additional proxies if support is insufficient.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

d0f25870f3ea405d18fab9fe924ee5a0f2c2d19f33d4ae1e979ad4f842d5eee3

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates